The TRM approach also provides the option of modifying the 4 per cent basic royalty rate for high income countries in case the originator’s price is considered excessive in those countries, or does not properly reflect the therapeutic value of the invention (UNDP/WHO Guidelines, p. 85). Members have to make available in their domestic legislation means to appeal the decisions taken by the initial granting authority (Article 31 (i), TRIPS Agreement). Such appeals may be filed with a court or an administrative authority distinct from and higher than the initial granting authority. In addition to appeals relating to the authorization of a compulsory license, a court or a distinct higher authority shall also review any decision concerning the remuneration of the patent holder (Article 31 (j), TRIPS Agreement). As the issue of compulsory licensing is closely related to non-IP issues such as public health, it might even be more appropriate, from a public policy point of view, to have a general court review the initial authority’s decisions on grant and remuneration. In addition, the review authority must not be subject to control by the authority that initially granted the license and decided on the compensation.